Member of the Quantitative Pharmacology Committee of Chinese Pharmacology Society 2019-2023
BS, University of Science and Technology of China; MS, University of Virginia; PhD in Pharmaceutical Sciences, University of Maryland; Postdoc in PK/PD modeling and simulation, University of Tennessee
12 Years of industrial experience in US and China spanning from preclinical to NDA, including Biogen (US), Janssen R&D China, BMS China, and Epimab
Lead multiple successful NDA submissions and approvals including long-acting coagulation factor Aprolix®、Eloctate®, multiple sclerosis mAb Zinbryta®, PD-1 mAb Opdivo® (China).
Published over 30 scientific manuscripts and book chapters
复星医药全球研发中心临床药理负责人，执行总监
中国药理学会定量药理学专业委员会第九界委员 2019 – 2023
中国科学技术大学生命科学学院本科，弗吉尼亚大学生物医学硕士，马里兰大学药学院制药学博士，田纳西大学药学院定量药理博士后
12年中美工业界创新药开发从临床前到申报上市临床药理和定量药理经验，曾就职于美国Biogen，强生中国，百时美施贵宝中国，初创企业岸迈
主导多个创新药上市的临床药理和定量药理工作包括长效凝血因子Aprolix®、Eloctate®，多发性骨髓瘤抗体Zinbryta®，PD-1抗体Opdivo®（中国）。
发表30多篇临床药理和定量药理学术论文和专著章节